<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880291</url>
  </required_header>
  <id_info>
    <org_study_id>GFB-024-102</org_study_id>
    <nct_id>NCT04880291</nct_id>
  </id_info>
  <brief_title>First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes</brief_title>
  <official_title>A First-In-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-024 as a Single Dose in Healthy Overweight and Obese Participants and as Multiple Doses in Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldfinch Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goldfinch Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy.&#xD;
      This study is the first time GFB-024 has been used in humans. The first part of the study&#xD;
      will assess the safety of a single dose of GFB-024 in healthy overweight and obese volunteers&#xD;
      and the effect of GFB-024 on the body as compared to an inactive placebo medication. The&#xD;
      second part of the study will assess the safety of repeated doses of GFB-024 in participants&#xD;
      with Type 2 diabetes and the effect of GFB-024 on the body as compared to an inactive placebo&#xD;
      medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human study. It is intended to provide the initial safety,&#xD;
      pharmacokinetics (PK), and pharmacology data for GFB-024 in humans. This study will comprise&#xD;
      a single ascending dose (SAD) escalation component in healthy overweight and obese volunteer&#xD;
      participants and a repeat-dose component to confirm repeat-dose safety, tolerability, PK, and&#xD;
      immunogenicity in participants with Type 2 diabetes mellitus. It will also explore potential&#xD;
      cannabinoid-1 receptor (CB1) activity, participant selection, pharmacodynamics, and&#xD;
      differential response biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">November 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability following single ascending doses of GFB-024</measure>
    <time_frame>Approximately 10 weeks</time_frame>
    <description>Number of participants with serious and other nonserious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability following repeated doses over 4 weeks of GFB-024</measure>
    <time_frame>Approximately 13 weeks</time_frame>
    <description>Number of participants with serious and other nonserious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize PK of GFB-024 following single ascending doses (Cmax)</measure>
    <time_frame>Approximately 10 weeks</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize PK of GFB-024 following single ascending doses (AUClast)</measure>
    <time_frame>Approximately 10 weeks</time_frame>
    <description>Area under the serum concentration-time curve from time zero to last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize PK of GFB-024 following repeated doses (Cmax)</measure>
    <time_frame>Approximately 13 weeks</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize PK of GFB-024 following repeated doses (AUClast)</measure>
    <time_frame>Approximately 13 weeks</time_frame>
    <description>Area under the serum concentration-time curve from time zero to last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the incidence and persistence of immunogenicity of GFB-024 following single ascending doses</measure>
    <time_frame>Approximately 10 weeks</time_frame>
    <description>Number of participants with confirmed antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the incidence and persistence of immunogenicity of GFB-024 following repeated doses</measure>
    <time_frame>Approximately 13 weeks</time_frame>
    <description>Number of participants with confirmed antidrug antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Diabetes Complications</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>GFB-024 SAD Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single ascending dose arm of GFB-024 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose arm of placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFB-024 Repeat-dose Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Repeat-dose arm of GFB-024 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat-dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeat-dose arm of placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFB-024</intervention_name>
    <description>Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody</description>
    <arm_group_label>GFB-024 Repeat-dose Active</arm_group_label>
    <arm_group_label>GFB-024 SAD Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Repeat-dose Placebo</arm_group_label>
    <arm_group_label>SAD Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 75 years of age at the time of signing informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) between 25.0 and 40.0 kg/m2, inclusive, at Screening.&#xD;
&#xD;
          -  Female participants will be of non-childbearing potential.&#xD;
&#xD;
          -  Male participants will agree to use contraception while on study intervention and for&#xD;
             at least 6 months after the last dose of study intervention.&#xD;
&#xD;
          -  SAD cohorts only: Participants must be in good health.&#xD;
&#xD;
          -  Repeat-dose cohort only: Type 2 diabetes mellitus (T2DM) treated with lifestyle&#xD;
             modification or metformin, and in otherwise good health except for well-controlled&#xD;
             common conditions associated with T2DM, such as hypertension and dyslipidemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or treatment for, psychiatric illness, including anxiety or depression&#xD;
             within 5 years of the Screening visit.&#xD;
&#xD;
          -  Participants with a history of attempted suicide or clinically significant suicidal&#xD;
             ideation.&#xD;
&#xD;
          -  History of cardiovascular disease.&#xD;
&#xD;
          -  Blood pressure &gt;155 mmHg systolic or &gt;95 mmHg diastolic.&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within 2 years prior to Screening.&#xD;
&#xD;
          -  Alcohol consumption of &gt;21 units per week for males and &gt;14 units for females. One&#xD;
             unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL)&#xD;
             wine.&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to more than one&#xD;
             class of drugs.&#xD;
&#xD;
          -  Positive hepatitis panel and/or positive human immunodeficiency virus test.&#xD;
             Participants whose results are compatible with prior immunization may be included.&#xD;
&#xD;
          -  SAD cohorts only: Fasting glucose &gt;126 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingela Danielsson, MD, PhD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trails</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Goldfinch Bio Clinical Trials Information</last_name>
    <phone>617-337-4200</phone>
    <email>clinicaltrials@goldfinchbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Weltens</last_name>
      <phone>512-615-2229</phone>
      <email>Maureen.Weltens@worldwide.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

